CTRI/2025/08/092392尚未招募3 期
A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy and Safety of Korglutide in Weight Management in Non-Diabetic Individuals with Elevated Body Fat and Normal Overweight BMI.
Biosite Research Private Limited1 个研究点 分布在 1 个国家目标入组 198 人开始时间: 2025年8月14日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 198
- 试验地点
- 1
- 主要终点
- Percent change in body
研究概览
简要总结
This clinical trial is a randomized, double-blind, placebo-controlled study, conducted over an 84-day period with a follow-up phase on days 28 and 56. The primary focus is to evaluate the effects of Korglutide in non-diabetic patients (BMI 22–26 kg/m² with high body fat percentage).
Participants will be randomized in a 2:1 ratio to receive either Korglutide or placebo. The study aims to measure not only weight loss but also fat mass reduction and muscle mass preservation, ensuring that Korglutide leads to effective fat reduction while maintaining muscle integrity. Baseline stratification by fat percentage levels will be implemented to reduce variability and improve statistical power. Body composition will be evaluated using bioelectrical impedance analysis (BIA), with assessments conducted at multiple time points.
The study encompasses four primary phases
- Screening
- Randomization and Baseline
- Treatment,
- Follow-Up.
Each phase is crucial for ensuring the validity and reliability of outcomes, with detailed processes and assessments aligned with regulatory requirements.
- Visit 1: Screening
- Visit 2: Baseline/Randomization (Day 0)
- Visit 3: Interim Assessment (Day 28)
- Visit 4: Interim Assessment (Day 56)
- Visit 5: End of Treatment (Day 84)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- Participant and Investigator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 75.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Males and females aged 18 to 75 years.
- •2.Body Mass Index (BMI) between 22 to 26 kg per m².
- •3.High body fat percentage, defined as less than and equal to 25 percent for males and less than and equal to 28 percnt for females.
- •4.Stable weight (plus minus 3 kg fluctuation) for at least 3 months prior to screening.
- •5.Fasting plasma glucose (FPG) less than 126 mg per dL and HbA1c less than 6.5 percent to confirm non-diabetic status.
- •6.Willingness to comply with the prescribed dietary and physical activity recommendations.
- •7.Non-smoker.
- •8.Vital signs are normal or deemed abnormal but clinically insignificant by the Investigator.
- •9.Males who are sterile or agree to use an approved method of contraception, with an approved method of contraception considered a barrier method (diaphragm, cervical cap, or condom) plus a contraceptive jelly (spermicidal foam, gel, film, cream, or suppository).
- •If the female sexual partner of the male is using an approved form of contraception (see inclusion criterion 10) or is not of child-bearing potential, the male is not required to be sterile or, if not sterile, to use an approved form of contraception.
- •10.Female subjects who are Postmenopausal (absence of menses for 1 year or more), Surgically sterilized, WOCBP who are non-lactating and have been using an effective form of birth control for a minimum of 6 months prior to screening and agree to continue using the effective form of birth control during the study and for 30 days after the treatment period.
- •11.Subjects who can provide informed consent and complying with all study procedures/requirements.
排除标准
- •Participants diagnosed with Type 1 or Type 2 diabetes, metabolic syndrome, or other metabolic disorders that affect weight regulation.
- •Prior history of bariatric surgery or any weight-loss procedure within the last five years.
- •3.Cardiovascular conditions: History of myocardial infarction, stroke, heart failure (NYHA class II-IV), or uncontrolled hypertension (SBP greater than 160 mmHg or DBP greater than 100 mmHg).
- •4.Presence of hypothyroidism, hyperthyroidism, Cushing’s syndrome, or any other endocrine disorder that may interfere with metabolic function.
- •5.Liver and kidney dysfunction: Patients with AST/ALT levels greater than 3 times the upper limit of normal, chronic liver disease, cirrhosis, or chronic kidney disease (eGFR less than 60 mL per min per 1.73 m²).
- •6.Use of weight-modulating medications: Any use of GLP-1 receptor agonists, corticosteroids, anabolic steroids, appetite suppressants, or other weight-modulating agents within three months prior to screening.
- •7.Women who are pregnant, planning to become pregnant, or breastfeeding during the study.
- •8.Participants with a prior diagnosis of anorexia nervosa, bulimia nervosa, binge-eating disorder, or any other eating disorder.
- •9.Current or recent alcohol or drug abuse within the past 12 months.
- •10.Any history of cancer within the past five years, except for successfully treated non-melanoma skin cancer.
- •11.Participation in other clinical trials: Enrollment in another clinical trial within the past 90 days.
- •12.Presence of major depressive disorder, schizophrenia, bipolar disorder, or other psychiatric illnesses that may impair compliance.
- •13.Participants with a known allergy to Korglutide or any of its excipients.
- •14.History of gastroparesis, inflammatory bowel disease (Crohn’s disease, ulcerative colitis), or chronic pancreatitis.
- •15.Presence of severe peripheral neuropathy, epilepsy, or neurodegenerative diseases that may impact study compliance.
- •16.Patients with HIV, active hepatitis B or C, or tuberculosis.
结局指标
主要结局
Percent change in body
时间窗: Baseline & Day 84
次要结局
- Percent change in waist hip ratio (WHR)(Baseline & Day 84)
- Proportion of participants achieving greater than equal to 5% and less than equal to 10% total weight loss(Baseline & Day 84)
- Percent change in visceral fat levels(Baseline & Day 84)
- Percent change in fat mass(Baseline & Day 84)
- Percent change in muscle mass(Baseline & Day 84)
- Percent change in fat percentage(Baseline & Day 84)
研究者
Dr Aditi Datta
Biosite Research Private Limited
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
QLS12010 in Participants With Moderate-to-severe Rheumatoid ArthritisNCT07377773Qilu Pharmaceutical Co., Ltd.180
已完成
1 期
Phase I Study of PollenVax in Patients With Mugwort Pollen-Induced Allergic RhinitisRhinitis AllergicNCT07317960Kazakh National Agrarian University30
招募中
2 期
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT07292714Mabwell (Shanghai) Bioscience Co., Ltd.360
招募中
2 期
A Study of SHR-2173 in Participants With Primary IgA NephropathyNCT07354932Guangdong Hengrui Pharmaceutical Co., Ltd84
招募中
2 期
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus ErythematosusNCT07447986Hangzhou Sumgen Biotech Co., Ltd.120